Literature DB >> 12846345

The importance of reaching lipid targets: statins and the prevention of atherosclerosis.

P Schwandt1.   

Abstract

To help prevent the development of coronary heart disease (CHD), the European and NCEP guidelines have recommended target cholesterol levels for all individuals. Lifestyle changes are advocated for individuals not achieving these targets. Intervention with lipid-modifying agents may be required for patients at high risk of a cardiovascular event and statins are generally recognised as first-line therapy. Unfortunately, large numbers of patients at risk of cardiovascular events are not being treated to the guideline targets. Primary care physicians are in a good position to improve lipid management by assessing risk factors, implementing lipid management strategies, monitoring whether targets are being reached and amending treatment appropriately. Furthermore, by educating and motivating patients,primary care physicians may improve compliance with lifestyle changes and medication. These approaches may help more patients to achieve recommended lipid levels and prevent the development of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12846345

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  3 in total

1.  ACE inhibitors in patients with vascular disease: should the PEACE trial change medical practice?

Authors:  Robert M Carey
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

2.  Plasma cholesterol and related lipid levels of seemingly healthy public service employees in Kampala, Uganda.

Authors:  G S Bimenya; J K Okot; H Nangosa; S A Anguma; W Byarugaba
Journal:  Afr Health Sci       Date:  2006-09       Impact factor: 0.927

3.  Trends in total cholesterol screening and in prescribing lipid-lowering drugs in general practice in the period 1994-2003.

Authors:  Stefaan Bartholomeeusen; Jan P Vandenbroucke; Carla Truyers; Frank Buntinx
Journal:  BMC Fam Pract       Date:  2008-06-30       Impact factor: 2.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.